Form 4: BioLife Solutions EVP Aby J. Mathew Executes Stock Options and Sells Shares
SEC Form 4 Filing
Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions, exercised stock options and sold 20,000 shares of common stock on September 18 and 19, 2024, according to a Form 4 filing with the SEC.
Summary
- Aby J. Mathew, the EVP & Chief Scientific Officer of BioLife Solutions Inc. (BLFS), executed stock options to purchase 20,000 shares of common stock at a price of $2.06 per share on September 18 and 19, 2024.
- Simultaneously, Mathew sold 20,000 shares of common stock in the open market.
- On September 18, 10,000 shares were sold at a weighted average price of $23.9, with prices ranging from $23.14 to $24.80.
- On September 19, 10,000 shares were sold at a weighted average price of $25.47, with prices ranging from $24.33 to $25.98.
- Following these transactions, Mathew directly owns 317,716 shares of BioLife Solutions Inc.
- Mathew also holds options to purchase 30,000 shares of common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral. It's a standard disclosure of stock option exercises and sales by an executive. The sales are conducted under a pre-arranged trading plan, which mitigates concerns about opportunistic trading.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company executives and their confidence in the company's prospects. Investors often monitor these filings to gauge sentiment and potential future stock performance.
Key Dates
| Date | Description |
|---|---|
| 05/04/2015 | Reporting person was granted an option to purchase 229,837 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. |
| 06/14/2024 | Date of adoption of Rule 10b5-1(c) trading plan. |
| 09/18/2024 | Date of first transaction: exercise of options and sale of 10,000 shares. |
| 09/19/2024 | Date of second transaction: exercise of options and sale of 10,000 shares. |
| 09/20/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.